HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

trisacryl gelatin microspheres

Subscribe to New Research on trisacryl gelatin microspheres

an acrylic co-polymer (trisacryl) which is then cross-linked with gelatin; used for targeted occlusion of the blood vessels; BioSphere Medical Inc

Also Known As:

Embosphere Microspheres; Embospheres; tris-acryl gelatin microspheres

Networked: 36 relevant articles (4 outcomes, 4 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pelage, Jean-Pierre: 4 articles (03/2009 - 01/2003)
2.	Laurent, Alexandre: 4 articles (03/2009 - 01/2003)
3.	Spies, James B: 4 articles (02/2007 - 07/2002)
4.	Wassef, Michel: 3 articles (03/2009 - 05/2004)
5.	Vervest, Harry A M: 2 articles (07/2007 - 02/2006)
6.	Smeets, Albert J: 2 articles (07/2007 - 02/2006)
7.	Lohle, Paul N M: 2 articles (07/2007 - 02/2006)
8.	Lampmann, Leo E H: 2 articles (07/2007 - 02/2006)
9.	Kroencke, Thomas J: 2 articles (07/2007 - 07/2005)
10.	Flick, Pamela: 2 articles (11/2005 - 08/2004)

Related Diseases

1.	Leiomyoma (Uterine Fibroids) 11/01/2004 - "PURPOSE: A French multicenter registry was set up to confirm the safety and efficacy of large calibrated tris-acryl gelatin microspheres for embolization of symptomatic fibroids. " 12/01/2008 - "Pregnancy after uterine fibroid embolization: follow-up of 100 patients embolized using tris-acryl gelatin microspheres." 02/01/2007 - "PURPOSE: To determine the long-term outcome of uterine fibroid therapy (UFE) using tris-acryl gelatin microspheres (TAGM). " 02/01/2007 - "Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study." 02/01/2004 - "Tris-acryl gelatin microspheres are a new embolic agent that is increasingly used for uterine fibroid embolisation. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 06/01/2008 - "In both cases, Onyx embolization provided effective preoperative tumor devascularization after the initial prolonged particulate embolization with Embospheres made little overall impact. " 01/01/2008 - "Given the known risk of recurrence in patients with persistent tumor enhancement after UAE, it is concluded that tris-acryl gelatin microspheres should be the preferred agent for UAE at this time." 02/01/2000 - "Intraoperative blood loss differed significantly between groups 1 and 2 and groups 1 and 3, but not between groups 2 and 3. The trisacryl gelatin microspheres were located more distally in tumor vessels than were the PVA particles of either size. " 12/01/2005 - "Administration of tris-acryl gelatin microspheres may be clinically advantageous during TACE, as it contributed to greater delivery of chemotherapy to tumor in the present study." 01/01/2007 - "Although several therapeutic options are available, we describe apalliative therapy for hepatic angiosarcoma utilizing transcatheter arterial chemoembolization (TACE) techniques incorporating the newer embolization agent Embospheres to locally target and treat this aggressive tumor." Order ALL the reference details at left...
3.	Infarction 01/01/2008 - "CONCLUSIONS: There was a significantly greater degree of tumor infarction in patients treated with tris-acryl gelatin microspheres during UAE than in patients who received PVA microspheres administered in accordance with a newly refined protocol. " 01/01/2008 - "Leiomyoma infarction after uterine artery embolization: a prospective randomized study comparing tris-acryl gelatin microspheres versus polyvinyl alcohol microspheres." 01/01/2008 - "PURPOSE: To determine the degree of leiomyoma infarction after uterine artery embolization (UAE) performed with tris-acryl gelatin microspheres or polyvinyl alcohol (PVA) microspheres. " 07/01/2002 - "CONCLUSIONS: Tris-acryl gelatin microspheres (Embospheres) are an effective embolic agent for UAE, causing infarction and significant decrease in leiomyoma volume." Order ALL the reference details at left...
4.	Bone Neoplasms (Bone Cancer) 09/01/2004 - "Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone neoplasms." 09/01/2004 - "The aim of this study was to compare the efficacy of trisacryl gelatin microspheres versus polyvinyl alcohol particles (PVA) in the preoperative embolization of bone neoplasms, on the basis of intraoperative blood loss quantified by the differences in preoperative and postoperative hematic levels of hemoglobin, hematocrit and erythrocytes count. " Order ALL the reference details at left...
5.	Meningioma (Meningiomas) 10/01/2004 - "Preoperative embolization of intracranial meningiomas with Embosphere microspheres." 02/01/2000 - "METHODS: In 30 consecutive patients, trisacryl gelatin microspheres (150-300 microm) were used for the preoperative superselective embolization of meningiomas (group 1). " 02/01/2000 - "CONCLUSION: Trisacryl gelatin microspheres may be effective in the preoperative embolization of meningiomas, producing significantly less blood loss at surgery than seen with PVA particles of either size, possibly because of the significantly more distal vascular penetration of the microspheres." 10/01/2004 - "The average time required for tumor extirpation was 244 minutes, while the average blood loss was 749 ml. CONCLUSIONS: Our experiences show that Embosphere microspheres are effective embolic agents in obstructing meningeal feeders of preoperatively treated meningiomas." 02/01/2000 - "Efficacy of trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of meningiomas." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Polyvinyl Alcohol
2.	Hemoglobins (Hemoglobin)
3.	trisacryl gelatin microspheres
4.	glucuronyl glucosamine glycan sulfate (Vessel)
5.	Carboplatin (JM8)
6.	ivalon sponge

Related Therapies and Procedures

1.	Microspheres (Microsphere)
2.	Uterine Artery Embolization
3.	Drug Therapy (Chemotherapy)
4.	Therapeutic Embolization

blog comments powered by Disqus

TREATMENT OPTIONS
for Leiomyoma,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 154 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>